Fig. 4

IRF2-deficient human and mouse melanomas are resistant to CPI therapy. A Diagram of experiments testing the WT (n=14) vs IRF2KO (n=12) B16F0 in vivo tumor growth in C57BL/6 mice after isotype control or αPD1 treatment. B Tumor growth was recorded until the end of the experiment. C & D Tumors were collected on day 17 and MHC I expression was analyzed by flow cytometry (C) and mRNA expression of MHC I pathway components were analyzed using qPCR method (D). E Another group of C57BL/6 mice (n=58) were subcutaneously injected with either WT (n=29) or IRF2KO (n=29) B16F0 cells and tumor growth was recorded for survival analysis. F Diagram of experiments testing the WT (n=14) vs IRF2KO (n=15) the A17 patient-derived human melanoma growth in NSG (n=6) and NSG with HuHSC (n=23) mice after isotype control or αPD1 treatment. G Tumor growth was recorded until the end of the experiment and (C) MHC I expression was analyzed by flow cytometry on day 55 and day 112. C, D & H Each dot represents a biological replicate and the curves on B and G show mean+SD. Statistical analysis was calculated by GraphPad Prism, **P < 0.05, **P < 0.01, ***P < 0.001